NEW YORK (GenomeWeb News) – Roche said this week it has proposed adding company CEO Severin Schwan to its board of directors, and that two members of its board, Bruno Gehrig and Lodewijk de Vink, will not stand for re-election to the board.
Roche also said that the following current board members will be proposed for another term: Andreas Oeri; Pius Baschera; Paul Bulcke; William Burns; Christoph Franz; DeAnne Julius; Arthur Levinson; Peter Voser; and Beatrice Weder di Mauro.
Phoenix Children's Hospital said this week that Robert Arceci and Timothy Triche will serve as co-directors of its new Matricaria Institute of Molecular Medicine.
Arceci will leave his position as director of pediatric oncology at the Johns Hopkins School of Medicine to join the institute at the end of this year. He also will be a full-time physician at Phoenix Children's and will serve as division chief of hematology and oncology at the hospital.
Triche's position is still under discussion, Phoenix Children's said, but he is expected to join the institute full-time at the end of a transition period.
Conrad Mir has joined Pressure BioSciences as chief financial officer. Mir has two decades of experience in investment banking, financial restructuring, and corporate reengineering, and he has held executive management roles and has sat on the boards of directors at several biotech companies, including serving as chairman and CEO of Genetic Immunity, and as executive director of Advaxis.
Pathogen identification company PathoGenetix said this week that Ann Merrifield is its new president and CEO. Merrifield has had a long career working with biologics, diagnostics services, and devices, including an 18-year term at Genzyme, where she was president of both its Biosurgery and Genetics businesses. Before working at Genzyme she was a partner with Bain & Company.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.